Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, International, Multicenter, Parallel Group, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Subjects With Peripheral Arterial Occlusive Disease Fontaine Stage IIB

NCT03469349 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT03469349
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03469349 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, International, Multicenter, Parallel Group, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Subjects With Peripheral Arterial Occlusive Disease Fontaine Stage IIB
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
May 1, 2018
Completion date
August 28, 2019
Enrollment
366 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral arterial diseases